Impact of prognostic factors on OS and RFS by univariate and multivariate analysis
| . | Univariate analysis: P . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR . | 95% CI . | P . | ||
| OS | ||||
| MRD postconsolidation | ||||
| Positive vs negative | < .001 | 2.38 | 1.03-5.45 | .04 |
| MRD postinduction | ||||
| Positive vs negative | .014 | 0.96 | 0.43-1.98 | NS |
| Karyotype/FLT3 risk | ||||
| Poor K/FLT3-ITD vs others | .006 | 1.19 | 0.65-1.17 | NS |
| Karyotype (MRC) | ||||
| Good vs intermediate/poor | .006 | 0.56 | 0.30-1.67 | NS |
| Postconsolidation treatment | ||||
| AuSCT vs chemotherapy | .006 | 2.58 | 0.69-9.59 | NS |
| ASCT vs chemotherapy | .035 | 4.16 | 1.25-13.8 | .02 |
| RFS | ||||
| MRD postconsolidation | ||||
| Positive vs negative | < .001 | 2.68 | 1.27-5.67 | .009 |
| MRD postinduction | ||||
| Positive vs negative | < .001 | 1.31 | 0.65-2.66 | NS |
| Karyotype/FLT3 risk | ||||
| Poor K/FLT3-ITD vs others | < .001 | 1.78 | 1.03-3.08 | NS |
| Karyotype (MRC) | ||||
| Good vs intermediate/poor | .007 | 0.79 | 0.37-1.69 | .038 |
| Postconsolidation treatment | ||||
| AuSCT vs chemotherapy | .13 | 2.44 | 1.06-5.64 | .036 |
| ASCT vs chemotherapy | .17 | 0.89 | 0.33-2.42 | NS |
| . | Univariate analysis: P . | Multivariate analysis . | ||
|---|---|---|---|---|
| HR . | 95% CI . | P . | ||
| OS | ||||
| MRD postconsolidation | ||||
| Positive vs negative | < .001 | 2.38 | 1.03-5.45 | .04 |
| MRD postinduction | ||||
| Positive vs negative | .014 | 0.96 | 0.43-1.98 | NS |
| Karyotype/FLT3 risk | ||||
| Poor K/FLT3-ITD vs others | .006 | 1.19 | 0.65-1.17 | NS |
| Karyotype (MRC) | ||||
| Good vs intermediate/poor | .006 | 0.56 | 0.30-1.67 | NS |
| Postconsolidation treatment | ||||
| AuSCT vs chemotherapy | .006 | 2.58 | 0.69-9.59 | NS |
| ASCT vs chemotherapy | .035 | 4.16 | 1.25-13.8 | .02 |
| RFS | ||||
| MRD postconsolidation | ||||
| Positive vs negative | < .001 | 2.68 | 1.27-5.67 | .009 |
| MRD postinduction | ||||
| Positive vs negative | < .001 | 1.31 | 0.65-2.66 | NS |
| Karyotype/FLT3 risk | ||||
| Poor K/FLT3-ITD vs others | < .001 | 1.78 | 1.03-3.08 | NS |
| Karyotype (MRC) | ||||
| Good vs intermediate/poor | .007 | 0.79 | 0.37-1.69 | .038 |
| Postconsolidation treatment | ||||
| AuSCT vs chemotherapy | .13 | 2.44 | 1.06-5.64 | .036 |
| ASCT vs chemotherapy | .17 | 0.89 | 0.33-2.42 | NS |
OS indicates overall survival; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; and NS, not significant.